AlphAIAlphAI — Financial news for AI agents
BenzingaNOV 182 min read$BCTX

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX)

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( NASDAQ:BCTX, BCTXW ) ) ( TSX:BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...

Original reporting
Benzinga · Globe Newswire
Published Nov 18, 2025, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2025, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$BCTXBullishMed
01

Why it matters

The presentation could serve as a catalyst for stock movement, contingent on data outcomes.

02

Market read

High relevance for biotech investors and analysts tracking cancer immunotherapy developments.

03

What to watch

Market-wide biotech downturns or macroeconomic factors could overshadow company-specific news.

Timing: Immediate, as the event is scheduled for 2025-11-18

Background

BriaCell is advancing immunotherapy treatments for cancer, with upcoming data presentations at SABCS 2025.

Company-level read

Ticker impact

$BCTXBullishHigh confidence
Context

The news pertains to BriaCell Therapeutics' upcoming presentation of clinical data at SABCS 2025, which could influence investor sentiment and stock performance.

Expected impact

Moderate increase in stock price within the next 1-2 weeks.

Evidence & confidence

The presentation of Phase 2 & 3 clinical data at a reputable conference is a significant milestone that can enhance credibility and attract investor interest.

Market effects

Sector

Potential positive impact on biotech sector sentiment

Regional

Limited regional impact, primarily affecting North American biotech stocks

Global

Moderate, as biotech conferences attract international attention

Counterpoint

What could challenge this read

The clinical data may not meet market expectations, leading to a sell-off despite the event's significance.

Key entities

  • Company
    BriaCell Therapeutics

    A clinical-stage biotechnology firm developing immunotherapies for cancer.

Read at source← All news

Related articles

SEP 20
$BCTXMedAI 8/10

Q&A: Advancing cancer biotech therapies with a multipronged approach

BriaCell Therapeutics (BCTX) develops targeted immunotherapies for cancer, focusing on 'off-the-shelf' cellular treatments. CEO Dr. Williams discussed their pipeline, including Bria-IMT in a Phase 3 trial for metastatic breast cancer and Bria-PROS+ for prostate cancer, which recently received FDA clearance. The company aims to overcome cost and scaling challenges of traditional therapies.

digitaljournal.com2 min
JUN 1
$BCTXMedAI 9/10

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

manilatimes.net6 min
MAY 26
$BCTXHighAI 9/10

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

manilatimes.net2 min
SEP 20
$JEFLow

Inside Jefferies’ months-long tussle with Glencore over Radiant

Jefferies Financial Group Inc. is in dispute with Glencore Plc over $526.4 million in overdue payments linked to Radiant World, an iron ore trader. Jefferies claims Glencore owes the amount, while Glencore denies any obligation. Emails show escalating tensions as Jefferies seeks information on invoices, with Glencore alleging Radiant World was involved in fraud. Radiant World and Sapphire Minmetals have filed a $2 billion lawsuit against Glencore, which denies the claims.

mining.com3 min
SEP 20
$HALHighAI 8/10

Halliburton (HAL) Wins Integrated Cyprus Contract. Can Broader Services Improve Returns?

Halliburton (HAL) secured a multi-year contract from Eni (E) for the Cronos ultra-deepwater project in Cyprus, covering integrated drilling and well services. The deal aims to boost revenue per well and improve operational efficiency, though profitability depends on pricing and delivery costs. HAL's Q2 Europe/Africa revenue rose 19% sequentially, partly driven by regional activity.

yahoo.com2 min